Terms: = Prostate cancer AND CD79B, ENSG00000007312, 974, P40259, IGB, B29 AND Treatment
19 results:
1. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for prostate cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.
Neylon J; Ma TM; Savjani R; Low DA; Steinberg ML; Lamb JM; Nickols NG; Kishan AU; Cao M
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1181-1191. PubMed ID: 38160916
[TBL] [Abstract] [Full Text] [Related]
2. A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant prostate cancer.
Alameddine Z; Niazi MRK; Rajavel A; Behgal J; Keesari PR; Araji G; Mustafa A; Wei C; Jahangir A; Terjanian TO
Curr Oncol; 2023 Oct; 30(10):9262-9275. PubMed ID: 37887569
[TBL] [Abstract] [Full Text] [Related]
3. Application of Dynamic Enhanced Magnetic Resonance Imaging Texture Analysis Combined with ADCs in Predicting Pelvic Lymph Metastasis of prostate cancer.
Yao L; Ding J; Li X; Yang J; Chen Z; Jia C; Duan Q
Arch Esp Urol; 2023 Aug; 76(6):383-388. PubMed ID: 37681328
[TBL] [Abstract] [Full Text] [Related]
4. Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte.
Yang C; Liu Z; Fang Y; Cao X; Xu G; Wang Z; Hu Z; Wang S; Wu X
J Transl Med; 2023 Jul; 21(1):465. PubMed ID: 37438820
[TBL] [Abstract] [Full Text] [Related]
5. Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.
Kiciak A; Clark W; Uhlich M; Letendre A; Littlechild R; Lightning P; Vasquez C; Singh R; Broomfield S; Martin AM; Huang G; Fairey A; Kolinsky M; Wallis CJD; Fung C; Hyndman E; Yip S; Bismar TA; Lewis J; Ghosh S; Kinnaird A
Cancer; 2023 Sep; 129(18):2864-2870. PubMed ID: 37424308
[TBL] [Abstract] [Full Text] [Related]
6. Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of prostate cancer: A Feasibility Study.
Wang Y; Feng G; Wang J; An P; Duan P; Hu Y; Ye Y; Li Y; Qin P; Song P
Comput Math Methods Med; 2022; 2022():8090529. PubMed ID: 35529273
[TBL] [Abstract] [Full Text] [Related]
7. Three-tiered Subclassification System of High-risk prostate cancer in Men Managed With Radical prostatectomy: Implications for treatment Decision-making.
Lamba N; Butler S; Mahal BA; Trinh QD; Rose B; King M; Orio P; Mouw KW; Martin N; Leeman JE; Feng FY; Nguyen PL; Muralidhar V
Urology; 2020 Nov; 145():197-203. PubMed ID: 32763323
[TBL] [Abstract] [Full Text] [Related]
8. Patterns of metastases of prostatic ductal adenocarcinoma.
Ranasinghe WKB; Brooks NA; Elsheshtawi MA; Davis JW; Bathala TK; Tang C; Troncoso P; Aparicio A; Tu SM; Pisters LL; Chapin BF
Cancer; 2020 Aug; 126(16):3667-3673. PubMed ID: 32453443
[TBL] [Abstract] [Full Text] [Related]
9. Ki-67 expression predicts biochemical recurrence after radical prostatectomy in the setting of positive surgical margins.
Shahait M; Nassif S; Tamim H; Mukherji D; Hijazi M; El Sabban M; Khauli R; Bulbul M; Abou Kheir W; El Hajj A
BMC Urol; 2018 Mar; 18(1):13. PubMed ID: 29506507
[TBL] [Abstract] [Full Text] [Related]
10. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract] [Full Text] [Related]
11. Laparoscopic versus open nephroureterectomy to treat localized and/or locally advanced upper tract urothelial carcinoma: oncological outcomes from a multicenter study.
Liu JY; Dai YB; Zhou FJ; Long Z; Li YH; Xie D; Liu B; Tang J; Tan J; Yao K; He LY
BMC Surg; 2017 Jan; 17(1):8. PubMed ID: 28095848
[TBL] [Abstract] [Full Text] [Related]
12. Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with prostate cancer Treated with Radical prostatectomy.
Boehm K; Larcher A; Tian Z; Mandel P; Schiffmann J; Karakiewicz PI; Graefen M; Huland H; Tilki D
J Urol; 2016 Jul; 196(1):82-8. PubMed ID: 26925872
[TBL] [Abstract] [Full Text] [Related]
13. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract] [Full Text] [Related]
14. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract] [Full Text] [Related]
15. Focal laser ablation of prostate cancer: numerical simulation of temperature and damage distribution.
Marqa MF; Colin P; Nevoux P; Mordon SR; Betrouni N
Biomed Eng Online; 2011 Jun; 10():45. PubMed ID: 21635775
[TBL] [Abstract] [Full Text] [Related]
16. Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study.
Biggs ML; Sorkin BC; Nahin RL; Kuller LH; Fitzpatrick AL
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):694-8. PubMed ID: 20582906
[TBL] [Abstract] [Full Text] [Related]
17. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
[TBL] [Abstract] [Full Text] [Related]
18. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.
Clark LC; Dalkin B; Krongrad A; Combs GF; Turnbull BW; Slate EH; Witherington R; Herlong JH; Janosko E; Carpenter D; Borosso C; Falk S; Rounder J
Br J Urol; 1998 May; 81(5):730-4. PubMed ID: 9634050
[TBL] [Abstract] [Full Text] [Related]
19. [Five-year trend in new patients with prostatic carcinoma].
Moriyama N; Akaza H; Sugimoto M; Taniguci J; Hara M; Fukutani K; Kitamura T; Higashihara E; Kishi H; Umeda T
Hinyokika Kiyo; 1988 Jun; 34(6):997-1001. PubMed ID: 3066215
[TBL] [Abstract] [Full Text] [Related]
